Vascular Solutions and Zerusa Limited Announce FDA Market Clearance for the Next...

Vascular Solutions and Zerusa Limited Announce FDA Market Clearance for the Next
Generation Guardian II Hemostasis Valve

MINNEAPOLIS and GALWAY, Ireland, Oct. 12, 2009 (GLOBE NEWSWIRE) -- Vascular
Solutions, Inc. (Nasdaq:VASC) and Zerusa Limited today announced that they have
received 510(k) clearance with the FDA for the sale of the Guardian(r) II Next
Generation hemostasis valve in the United States. Under the terms of an
agreement between the two companies from July 2007, Vascular Solutions is the
exclusive distributor of the Guardian device in the United States. Zerusa
recently began the rollout of its CE marked Guardian II launch through its
distribution network in Europe, the Middle East and other markets.

Howard Root, Chief Executive Officer of Vascular Solutions, commented: "We're
delighted to be able to offer this next generation of the Guardian hemostasis
valve to our customers through our 85+ employee direct U.S. sales force. The
device enhancements contained in this new device are well suited to our U.S.
customers, and we're looking forward to making an expanded impact with this
product in the marketplace."

Liam Mulloy, Chief Executive Officer of Zerusa Limited, commented: "We
appreciate all the market feedback both from Vascular Solutions and our other
partners to date. This has directly led to device enhancements on our Guardian
II hemostasis valve - while maintaining the key benefits appreciated by our
customers worldwide such as blood loss minimization, management of multiple
devices and ease of use. We look forward to building on our relationship with
Vascular Solutions to further develop the U.S. market opportunity."

About Zerusa Limited

Zerusa Limited designs, develops and markets minimally invasive medical devises
for the diagnosis and treatment of vascular disease.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on
developing unique clinical solutions for coronary and peripheral vascular
procedures. The company's product line consists of five major categories:
hemostat (blood clotting) products, extraction (clot removal) catheters, vein
products, specialty catheters and access products. Vascular Solutions delivers
its proprietary and distributed products to interventional cardiologists,
interventional radiologists and vascular surgeons through its direct U.S. sales
force and international distributor network.

The information in this press release contains forward-looking statements that
involve risks and uncertainties. Our actual results could differ materially from
those anticipated in these forward-looking statements. Important factors that
may cause such differences include those discussed in our Annual Report on Form
10-K for the year ended December 31, 2008 and other recent filings with the
Securities and Exchange Commission. The risks and uncertainties include, without
limitation, risks associated with the need for adoption of our new products,
limited working capital, lack of sustained profitability, exposure to
intellectual property claims, exposure to possible product liability claims, the
development of new products by others, doing business in international markets,
limited manufacturing experience, the availability of third party reimbursement,
and actions by the FDA.

For further information, connect to www.vascularsolutions.com.

-0-
CONTACT: Vascular Solutions, Inc.
Howard Root, CEO
James Hennen, CFO
(763) 656-4300